Just when the appetite for European biotech was showing signs of a healthy recovery from the 2001 venture fallout, along comes a recession. But with LP appetite for the buyout market at an all-time low, now could be the time for the smart investors to take the plunge in one of the few sectors that still offers double-digit returns.
